<DOC>
	<DOCNO>NCT00242788</DOCNO>
	<brief_summary>The primary objective Phase I part study determine recommend dose capecitabine administer combination ZD1839 250 mg orally daily subject advance metastatic colorectal cancer assess DLTs . The primary objective Phase II part study estimate objective response rate ( complete response [ CR ] partial response [ PR ] ) study closure ZD1839 administer combination capecitabine subject advance metastatic colorectal cancer use Response Evaluation Criteria Solid Tumours ( RECIST ) .</brief_summary>
	<brief_title>IRESSA™ In Combo With Xeloda™ Advanced Colorectal Cancer Patients After 1st-Line Chemo Failure</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>18 year old , Histologicallyconfirmed colorectal carcinoma , Nonresectable metastatic locally advanced disease , Objective progression one prior chemotherapeutic regimen metastatic locally advanced disease interval least 4 week last administration chemotherapy first administration study treatment , Measurable lesion accord RECIST , life expectancy 12 week , World Health Organisation ( WHO ) performance status 0 , 1 2 . 1 . Prior adjuvant chemotherapy diseasefree interval le 6 month Known leptomeningeal central nervous system ( CNS ) metastases Known severe hypersensitivity ZD1839 excipients product Known , severe hypersensitivity capecitabine excipients product Any evidence clinically active interstitial lung disease ( subject chronic stable radiographic change asymptomatic need exclude ) Other coexist malignancy malignancy diagnose within last 5 year exception basal cell carcinoma cervical cancer situ Any unresolved chronic toxicity great CTC grade 1 previous anticancer therapy Absolute neutrophil count ( ANC ) less 1500 mm3 ( 1.5 x 109/litre [ L ] ) , platelets less 100 000 mm3 ( 100 x 109/L ) haemoglobin le 10 g/dl Serum bilirubin great 1.5 time upper limit reference range ( ULRR ) Serum creatinine great 1.25 time ULRR Creatinine clearance 30 mL/min ( Cockroft Gault ) Alkaline phosphatase ( ALP ) great 5 time ULRR great 20 time ULRR subject know bone metastasesAlanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) great 2.5 time ULRR demonstrable liver metastasis , great 5 time ULRR presence liver metastases Prothrombin time ( PT ) activate partial thromboplastin time ( aPTT ) less 70 % normal laboratory value As judged investigator , evidence severe uncontrolled systemic disease ( e.g. , unstable uncompensated respiratory , cardiac , hepatic , renal disease ) Evidence significant clinical disorder laboratory find make undesirable subject participate study Pregnancy breast feeding ( woman childbearing potential ) Concomitant use phenytoin , carbamazepine , rifampicin barbiturate Treatment nonapproved investigational drug within 30 day Day 1 study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Colorectal Cancer</keyword>
</DOC>